Evaluating the Impact of Narcan-Related Healthcare Policies on Opioid Use in the United States

This interdisciplinary essay investigates the extent to which healthcare policies regarding Narcan (naloxone) have mitigated the opioid crisis in the United States. The author employs a dual-lens approach, combining biological analysis of $\mu$-opioid receptor antagonism with economic frameworks focusing on negative and positive consumption externalities.

The research concludes that while policies like Medicaid expansion and over-the-counter accessibility have significantly increased overdose reversals and reduced hospitalizations, their impact is limited by structural inequalities and the absence of systemic addiction treatment. The paper is distinguished by its synthesis of clinical data and economic market failure models to evaluate public health outcomes.